- Home
- GSL vs DNTH Comparison
GSL vs DNTH Comparison
Compare GSL & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSL
- DNTH
- Stock Information
- Founded
- GSL 2007
- DNTH 2015
- Country
- GSL Greece
- DNTH United States
- Employees
- GSL N/A
- DNTH N/A
- Industry
- GSL Marine Transportation
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- GSL Consumer Discretionary
- DNTH Health Care
- Exchange
- GSL Nasdaq
- DNTH Nasdaq
- Market Cap
- GSL 758.7M
- DNTH 657.0M
- IPO Year
- GSL 2006
- DNTH N/A
- Fundamental
- Price
- GSL $22.09
- DNTH $19.59
- Analyst Decision
- GSL Strong Buy
- DNTH Strong Buy
- Analyst Count
- GSL 1
- DNTH 8
- Target Price
- GSL $29.00
- DNTH $54.33
- AVG Volume (30 Days)
- GSL 260.4K
- DNTH 251.8K
- Earning Date
- GSL 05-19-2025
- DNTH 05-16-2025
- Dividend Yield
- GSL 8.16%
- DNTH N/A
- EPS Growth
- GSL 17.78
- DNTH N/A
- EPS
- GSL 9.67
- DNTH N/A
- Revenue
- GSL $705,529,000.00
- DNTH $6,235,000.00
- Revenue This Year
- GSL $1.84
- DNTH N/A
- Revenue Next Year
- GSL N/A
- DNTH N/A
- P/E Ratio
- GSL $2.27
- DNTH N/A
- Revenue Growth
- GSL 5.82
- DNTH 120.63
- 52 Week Low
- GSL $17.73
- DNTH $13.37
- 52 Week High
- GSL $30.32
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- GSL 58.00
- DNTH 45.90
- Support Level
- GSL $21.26
- DNTH $20.76
- Resistance Level
- GSL $22.23
- DNTH $22.14
- Average True Range (ATR)
- GSL 0.49
- DNTH 1.50
- MACD
- GSL 0.18
- DNTH -0.13
- Stochastic Oscillator
- GSL 94.31
- DNTH 5.53
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.